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Background: Next-generation sequencing (NGS) of tumour samples is a critical component of personalised cancer
treatment, but it requires high-quality DNA samples. Routine neutral-buffered formalin (NBF) ﬁxation has detrimental
effects on nucleic acids, causing low yields, as well as fragmentation and DNA base changes, leading to signiﬁcant
artefacts.
Patients and methods: We have carried out a detailed comparison of DNA quality from matched samples isolated
from high-grade serous ovarian cancers from 16 patients ﬁxed in methanol and NBF. These experiments use tumour frag-
ments and mock biopsies to simulate routine practice, ensuring that results are applicable to standard clinical biopsies.
Results: Using matched snap-frozen tissue as gold standard comparator, we show that methanol-based ﬁxation has
signiﬁcant beneﬁts over NBF, with greater DNA yield, longer fragment size and more accurate copy-number calling using
shallow whole-genome sequencing (WGS). These data also provide a new approach to understand and quantify artefac-
tual effects of ﬁxation using non-negative matrix factorisation to analyse mutational spectra from targeted and WGS data.
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Conclusion: We strongly recommend the adoption of methanol ﬁxation for sample collection strategies in new clinical
trials. This approach is immediately available, is logistically simple and can offer cheaper and more reliable mutation calling
than traditional NBF ﬁxation.
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introduction
Although microscopic examination of formalin-ﬁxed parafﬁn-
embedded (FFPE) material remains crucial in cancer diagnosis,
next-generation sequencing (NGS) of tumour DNA has
emerged as a powerful diagnostic tool [1] and is a central com-
ponent of personalised medicine initiatives. NGS relies heavily
on high-quality DNA, and snap-frozen (SF) samples are pre-
ferred because formalin ﬁxation induces chemical modiﬁcations
and degradation of DNA [2, 3].
Comprehensive diagnostic strategies and translational re-
search protocols therefore currently demand two samples, one
SF for molecular analysis and the other FFPE for routine
haematoxylin and eosin staining (H&E) and immunohisto-
chemistry (IHC). Processing of SF samples for NGS has several
disadvantages, including reduced ability to microdissect tumour
material and signiﬁcantly increased costs [4, 5]. In particular,
there are signiﬁcant barriers to obtaining SF material in large-
scale clinical trials, where samples are typically collected from
multiple hospitals in different countries. Therefore, alternatives
to formalin-based ﬁxation are required to circumvent the need
for fresh-frozen sampling.
Methanol-based ﬁxation has emerged as a promising such
alternative [5–7] (supplementary Table S5, available at Annals
of Oncology online). Universal molecular ﬁxative (UMFIX) has
been shown to be superior for IHC to neutral-buffered formalin
(NBF), and gives higher yield and molecular weight of extracted
DNA and RNA [5, 6, 8]. In addition, prolonged exposure to
methanol ﬁxatives may have fewer deleterious effects on DNA/
RNA quantity and quality than NBF [3, 5]. However, potential
NGS sequencing artefacts from methanol ﬁxation have not
been studied.
Here, we have tested the suitability of DNA extracted after
methanol-based ﬁxation for NGS assays compared with DNA
from matched NBF and fresh-frozen tissues. We studied high-
grade serous ovarian cancer (HGSOC) samples because they
have ubiquitous TP53 mutation and TP53 sequences have been
extensively studied for ﬁxation artefacts [9, 10]. HGSOC also
has marked genomic rearrangement and copy-number abnor-
malities (CNAs), which allow stringent inspection of the effects
of DNA fragment length size on CNA proﬁling.
patients andmethods
sample acquisition and processing
Three equal fragments were macrodissected from tumour specimens
removed from 16 patients, median age 62, with HGSOC undergoing debulk-
ing surgery. In addition, mock biopsies of the tumour were taken from 12
cases with a 16G core biopsy gun. All samples were reviewed by at least two
pathologists and ﬁxed in 10% NBF (Genta Medical, York, UK)), UMFIX
(Sakura Finetek, Thatcham, UK) or SF (liquid nitrogen). Matched normal
tissue controls were processed in parallel. Full clinical details are given in
supplementary Table S1, available at Annals of Oncology online.
immunohistochemistry
5 µm sections of NBF and UMFIX ﬁxed material were stained for CK7, p53,
PAX8, WT1 and CK20 using established clinical protocols in the
Department of Pathology, Queen Elizabeth University Hospital, Glasgow,
with additional optimization for WT1 staining of UMFIX tissues. Staining
and image analysis protocols, as well as all histoscore data, are described in
supplementary material, available at Annals of Oncology online.
DNA extraction and quantiﬁcation
DNA was extracted using QIAmp DNA Micro and AllPrep DNA/RNA
Micro Kit for UMFIX/NBF-ﬁxed and SF tumours, respectively. DNA size
distribution and quality were assessed by qPCR with Illumina FFPE QC Kit
and KAPA hgDNA Quantiﬁcation and QC Kit, respectively.
tagged-amplicon sequencing (TAm-seq)
The coding regions of TP53, PTEN, EGFR, PIK3CA, KRAS and BRAF were
sequenced by TAm-Seq as described previously [11] on an Illumina MiSeq
using PE-125 bp protocols. Data analysis is described in supplementary ma-
terial, available at Annals of Oncology online.
shallow whole-genome sequencing (sWGS)
WGS libraries were prepared from 100 ng DNA using modiﬁed TruSeq
Nano DNA LT Sample Prep Kit protocol. Library quality and quantity were
assessed with DNA-7500 kit on 2100 Bioanalyzer and with Kapa Library
Quantiﬁcation kit according to the original protocols, respectively. Eighteen
barcoded libraries were pooled together in equimolar amounts and each
pool was sequenced on HiSeq2500 in SE-50 bp mode. Analysis methods are
described in supplementary material, available at Annals of Oncology online.
mutation signature analysis
Non-negative matrix factorisation was carried out to identify mutation
signatures [12] in relation to different ﬁxation (supplementary material,
available at Annals of Oncology online). All non-reference base changes
observed across the sequencing data were interrogated from both TAm-Seq
and sWGS data.
results
Figure 1 summarises the study design and the ﬂow of samples
through the study. Additional REMARK data are provided in
supplementary material, available at Annals of Oncology online.
methanol ﬁxation yields higher yield and size of
DNA fragments than buffered formalin
There was no signiﬁcant difference in tumour cellularity and
TP53 allele fraction between UMFIX and NBF samples, thus
allowing a direct comparison of DNA metrics (supplementary
Figure S1, available at Annals of Oncology online). Quantiﬁcation
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of extracted DNA showed similar yields of small (90 bp) frag-
ments from UMFIX and SF samples, both of which were sig-
niﬁcantly higher than from NBF (Figure 2A). As expected, SF
samples showed the highest yields of large fragments (129 bp,
305 bp), but yields from UMFIX samples were still signiﬁcantly
higher than NBF (Figure 2B).
copy-number calling in methanol-ﬁxed material
is superior to formalin
Copy-number proﬁles from sWGS were compared for
correlation and variance of copy-number abnormality (CNA)
estimation, using SF as gold standard. UMFIX showed superior
copy-number proﬁles compared with NBF, with 9 of 11
biopsies and 10 of 12 surgical samples showing higher correl-
ation with the matched SF (Figure 2C). UMFIX also had lower
noise for segmental copy-number estimation than NBF
(Figure 2D).
single-nucleotide sequencing noise frommethanol-
ﬁxed material is comparable with SF and NBF
We analysed low-level sequence noise using 255 376 ob-
served non-reference bases in the sWGS and TAm-Seq data.
All analysed mutations were ﬁltered using dbSNP speciﬁcally
to exclude germline SNPs. Analysis of the ﬂanking bases
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Figure 1. Study design. (A) Operative specimens from women undergoing surgery for HGSOC were sampled with a scalpel to acquire three surgical tumour
samples and a 16G needle was used to obtain three mock biopsies. Matched surgical and biopsy samples from each case, with matched control tissue, were pro-
cessed in parallel with ﬁxation in NBF or UMFIX, or SF before downstream analysis. (B) Sample workﬂow: numbers of patients (P) and samples (S) used for
analysis. Bx, biopsy; Tu, surgical tumour fragment; Ctrl, control tissue.
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around each base change revealed three mutation signatures
(Figure 3A): signature 1 was dominated by non-CpG C>A
transversions and C>T transitions; Signature 2 had high rates of
T>A, C>A, T>C and C>T transitions, with the latter enriched in
the trinucleotide context NCA (where N indicates any base);
Signature 3 showed T>C and CpG-related C>T transitions. A
breakdown of the contribution of each signature across four cat-
egories (base changes common to all samples, changes unique
to SF, UMFIX and NBF) showed that the common changes
(containing a collection of both true SNVs and typical errors)
were dominated by Signature 3, whereas the other categories
were a mix of Signatures 1 and 2 (Figure 3B).
single-nucleotide variant calling frommethanol-
ﬁxed material is comparable with fresh-frozen
SNVs were called using TAm-Seq of 66 samples yielding 546
variants. Manual curation of these variants revealed lower average
sensitivity and speciﬁcity for NBF compared with SF and UMFIX,
albeit not signiﬁcantly (Figure 3C).
methanol ﬁxation permits high-quality H&E and IHC
analyses
Tissue morphology (H&E staining) of UMFIX samples was
comparable with NBF ﬁxation. Overall, differences between
UMFIX
A
C
SF
NBF
–4 –2 0 2 4
*
*
Biopsy
Illumina DNA quantification (90 bp)
–4 –2 0 2
–DCq
4
*
*
*
*
*
Surgery
UMFIX
D
SF
Fi
xa
tiv
e
NBF
0.00 0.01 0.03 0.04
Variance
0.05
Biopsy
Segmented copy-number noise
0.02 0.00 0.01 0.03 0.04 0.050.02
Surgery
UMFIX
B
SF
NBF
*
*
*
Biopsy
KAPA DNA quantification (129 and 305 bp)
*
*
*
*
*
*
*
*
*
*
Q129/Q41
*
*
*
*
Surgery
*
*
*
*
*
*
*
*
*
*
UMFIX
SF
NBF
0.0 0.5 1.0 1.5 2.0 0.50.0 1.0 1.5
Q305/Q41
2.0
P2 P3 P4 P5
Segmented copy-number correlation with SF (x-axis)
P6 P8 P9 P11 P13 P14 P15 P16
Biopsy
N
BF
Biopsy
UM
FIX
Surgery
N
BF
Surgery
UM
FIX
r= 0.71 r= 0.49 r= 0.72 r= 0.85 r= 0.79 r= 0.85 r= 0.96 r= 0.83 r= 0.87 r= 0.75 r= 0.92
r= 0.81 r= 0.41 r= 0.79 r= 0.82 r= 0.81 r= 0.91 r= 0.98 r= 0.91 r= 0.94 r= 0.89 r= 0.95
r= 0.75 r= 0.4 r= 0.77 r= 0.91 r= 0.83 r= 0.8 r= 0.94 r= 0.09 r= 0.86 r= 0.91 r= 0.94
r= 0.94
r= 0.92
r= 0.92 r= 0.27 r= 0.82 r= 0.81 r= 0.85 r= 0.87 r= 0.95 r= 0.92 r= 0.94 r= 0.96 r= 0.95
Figure 2. DNA yield and copy-number calling performance. Box plots show results of PCR assays for DNA size after extraction from SF, NBF and methanol
(UMFIX) ﬁxation from matched biopsy and surgical samples from 11 HGSOC patients. (A) Observed ΔCq values for DNA yield of 90 bp fragments (negative
ΔCq values are shown for convenience). *P < 0.05, **P < 0.005, ***P < 0.0005. (B) Observed Q ratios for 129 bp/41 bp (top) and 305 bp/41 bp (bottom) frag-
ments. Vertical brackets indicate Wilcoxon rank-sum test for difference in means: *P < 0.05, **P < 0.005, ***P < 0.0005. (C) Scatter plots show correlation
between median normalised copy-number proﬁles from shallow WGS of SF compared with NBF or UMFIX biopsy and surgical samples from 12 patients.
Spearman’s rank-sum correlation rho is shown. Gray background (orange online) indicates plots with the highest correlation between UMFIX and NBF for
each patient sample (biopsy or surgery). (D) Boxplots show an observed variance for each copy-number segment (n = 90 312) in 69 samples from 12 patients.
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UMFIX and NBF were not diagnostically signiﬁcant (Figure 4A).
Statistically signiﬁcant correlation was found between quantitative
IHC histoscores in UMFIX and NBF-ﬁxed samples for key
HGSOC markers (p53, CK7, PAX8, WT1). CK20 was uniformly
negative in all tumour samples, regardless of ﬁxative (data not
shown). There was no signiﬁcant difference in median histoscore
between the two sample sets for p53, CK7 and PAX8 (Figure 4B).
discussion
The most important variables for NGS assays are DNA quality
and yield. Formalin ﬁxation can induce severe effects on the
structure and integrity of DNA causing C>T, A>G, G>T, G>C
and A>T base changes, methylene bridge formation, DNA de-
naturation and DNA fragmentation [6, 13–15]. After NGS,
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Figure 3. Single-nucleotide noise proﬁles and variant calling performance. (A) Bar plots of the three somatic mutation signatures (S1–S3) identiﬁed by non-
negative matrix factorisation using all non-reference bases observed in sWGS and TAm-SEQ sequencing data in 69 samples from 12 patients (n = 255 376). Bar
plots are grouped by the observed base change with individual bars showing the proportion observed at different trinucleotide sequences. (B) Stacked bar plots
show the proportion of the three mutation signatures observed only in SF and NBF or UMFIX ﬁxed samples compared with signatures present in all samples
from an individual patient (common). (C) Sensitivity (top) and speciﬁcity (bottom) for manually curated SNV calls (n = 546) from TAm-SEQ of biopsy and
surgical samples from 11 patients. Bars indicate the 95% conﬁdence interval around the indicted mean.
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Figure 4. H&E staining and IHC scoring. (A) H&E staining of tumour fragments (left) and biopsies (right) frommatched tissues ﬁxed in NBF and UMFIX. Bars re-
present 100 µm. (B) Representative images (left) show IHC staining for p53, PAX8, CK7, WT1 on matched NBF and UMFIX tissues. Quantitative histoscores
(middle) of intensity of staining for each IHC marker on tumour fragments [dark gray points (pink online)], biopsies [light gray points (orange online)] and control
tissue [black points (blue online)] samples. Spearman’s rank-sum correlation rho is shown (P < 0.001 for all analyses). Paired data plots (right) show comparison of
median histoscores from paired UMF- and NBF-ﬁxed tissues for each IHCmarker. Median scores were only signiﬁcantly different for WT staining (P = 0.011).
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these chemical modiﬁcations result in greater SNV artefacts,
higher sequence duplication rates, smaller insert sizes and lower
fractions of mappable reads [16, 17].
We evaluated whether methanol-based ﬁxation can reduce
these detrimental artefacts when attempting to identify true
somatic SNVs and accurate copy-number from clinical material.
We show that UMFIX ﬁxation yields longer ampliﬁable DNA
fragments, in agreement with previous reports [3, 5, 8], which
improves our ability to call DNA copy-number accurately. We
show that SNV calling from UMFIX DNA has similar perform-
ance to DNA from SF tissues and that traditional H&E staining
and IHC scoring can be carried out on UMFIX-embedded
samples with minimal optimisation.
These ﬁndings are clinically highly important: although
attempts have been made to reduce noise induced by formalin
ﬁxation (e.g. increasing targeted sequencing coverage or redu-
cing C>T transitions with UDG treatment), these methods only
mitigate some sources of noise when calling SNVs and do not
improve the ability to call CNA [18, 19]. CNA detection is more
challenging than SNV detection and remains the major clinical
need for personalised treatment approaches in HGSOC.
In addition, we have used a state-of-the-art computational
approach to perform in-depth exploration of the low-level
sequence noise introduced by ﬁxation and sample processing.
In an advance over previous approaches, we modelled the trinu-
cleotide context of each base change and de-convolved distinct
trinucleotide noise signatures. This computational approach has
previously been used to identify signatures in collections of
SNVs observed across thousands of tumours, and these signa-
tures used to infer underlying mutational processes [12]. In our
data, we identiﬁed three distinct trinucleotide signatures.
Signature 3 has high similarity to a previously identiﬁed CpG-
age-related cytosine deamination (C>T) signature (signature 1B
[12]), and a recently uncovered sequence error signature [20].
However, signatures 1 and 2 are novel and have no similarity to
previously described signatures. In particular, they show high
rates of C>T transition but not in CpG dinucleotide contexts.
As expected, signature 3 contributed only to the set of base
changes common to all samples across a patient. In contrast, sig-
natures 1 and 2 contributed only to the base changes exclusive
to SF, UMFIX or NBF samples. This suggests that the sequen-
cing noise represented by these two signatures (C>T not at
CpG) is induced through sample processing. The two ﬁxative
conditions showed a slightly increased contribution to signature
1 compared with SF, suggesting that ﬁxation may have a speciﬁc
effect. However, larger studies are required to achieve the power
to discern this. This approach to modelling sequence noise
provides powerful tools to explore sequencing artefacts and an
analytical framework to understand the mechanisms behind
their creation. Further studies with high coverage WGS are now
underway to reﬁne these data.
There are no data on the effects of long-term methanol ﬁx-
ation on DNA quality or quantity, and this study utilised
samples collected no more than 6 months before analysis. With
FFPE material, it is possible to isolate DNA from long-term
archived samples [21], although factors such as duration of ﬁx-
ation, age of the sample, exposure to heat and light, as well as
the concentration, buffering and age of the formalin, can all in-
ﬂuence DNA quality and extent of sequence artefact [22].
Careful longitudinal analyses will be required to ascertain
whether similar problems emerge in UMFIX samples.
We speciﬁcally did not examine RNA in this study. There are
several previous publications on the utility of RNA extracted
from methanol-ﬁxed specimens in PCR and microarray assays,
including from samples stored at room temperature for up to 8
weeks [5, 23]. However, we are not aware of any study assessing
RNA sequencing or RNA proﬁling of samples extracted from
methanol-ﬁxed tissue—again, future studies will be required to
conﬁrm whether RNA extracted from methanol can be reliably
used in such assays.
In summary, whilst SF samples remain the gold standard for
nucleic acid extraction from tumour material at present, there
are signiﬁcant costs associated with such samples in clinical
trials and NGS-based personalised medicine studies. A key ad-
vantage of methanol ﬁxation is that it allows easy collection and
embedding of tumour material with associated economies for
pathological veriﬁcation and microdissection. Based on our
ﬁndings of superior DNA quality, we recommend that UMFIX
be routinely adopted for collection and storage of clinical cancer
specimens for large-scale genomic analysis.
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TP53mutational status is predictive of pazopanib
response in advanced sarcomas
K. Koehler1, D. Liebner1,2 & J. L. Chen1,2*
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Background: To investigate whether TP53 DNA mutational status impacts progression-free survival (PFS) in patients with
advanced sarcomas (soft tissue sarcoma) treated with vascular endothelial growth factor receptors (VEGFR) inhibition.
Patients and methods:We retrospectively reviewed 19 cases of patients treated at the Ohio State James Comprehensive
Cancer Center with advanced sarcoma treated with VEGFR inhibition who also had next-generation sequencing of their
tumors (via FoundationOne Heme panel). We evaluated TP53 as well as mutations that were observed in at least 20% of
patients and evaluated its contribution to PFS using the Kaplan–Meier survival analysis of available radiology end points.
Results:Mutations that were observed in at least 20% of patients included TP53 and Rb1. Only TP53 was predictive of PFS
in the context of VEGFR inhibition. The PFS of patients with TP53 mutations was signiﬁcantly greater than TP53 wild-type
tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% conﬁdence interval
0.09–0.83)].
*Correspondence to: Dr James L. Chen, Department Biomedical Informatics/Division of
Bioinformatics, The Ohio State University, 1800 Cannon Dr/250 Lincoln Tower/Columbus,
OH 43210-1267, USA. Tel: +1-614-366-1525; E-mail: james.chen@osumc.edu
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